<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Inbox Robot: Urological Diseases News</title>
<link>http://www.inboxrobot.com/news/urological-diseases</link>
<description>Constantly updated news and information about a variety of topics.</description><item>
<title>Report: China to issue blacklist of harmful food additives</title>
<link>http://www.inboxrobot.com/news.php?fid=202006708</link>
<pubDate>5 Dec 2008 13:56 GMT</pubDate>
<description>
...  said. The ministry this week issued a new count of 294,000 babies who suffered urinary problems from drinking contaminated infant formula, a six-fold increase from the last tally in  ...
</description>
</item><item>
<title>FDA Sends AstraZeneca Letter about Seroquel</title>
<link>http://www.inboxrobot.com/news.php?fid=202003862</link>
<pubDate>5 Dec 2008 13:53 GMT</pubDate>
<description>
...  of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Vimpat (lacosamide) is  ...  with benign prostatic hyperplasia (BPH), or enlarged prostate. Cinryze is a C1-esterase inhibitor indicated for  ...
</description>
</item><item>
<title>DiagnoCure announces fourth quarter and full year 2008 earnings conference call and &amp;hellip;</title>
<link>http://www.inboxrobot.com/news.php?fid=202003693</link>
<pubDate>5 Dec 2008 13:53 GMT</pubDate>
<description>
...  strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure&#39;s proprietary molecular marker. This test is also available through  ...
</description>
</item><item>
<title>New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn&#39;s Patients With Fistulizing</title>
<link>http://www.inboxrobot.com/news.php?fid=202003191</link>
<pubDate>5 Dec 2008 13:52 GMT</pubDate>
<description>
...  than with placebo (n=614) were upper respiratory infection (20% CIMZIA (R) , 13% placebo), urinary tract infection (7% CIMZIA (R) , 6% placebo), and arthralgia (6% CIMZIA (R) ,  ...
</description>
</item><item>
<title>New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn&#39;s Patients With Fistulizing Disease</title>
<link>http://www.inboxrobot.com/news.php?fid=202003152</link>
<pubDate>5 Dec 2008 13:52 GMT</pubDate>
<description>
...  than with placebo (n=614) were upper respiratory infection (20% CIMZIA (R) , 13% placebo), urinary tract infection (7% CIMZIA (R) , 6% placebo), and arthralgia (6% CIMZIA (R) ,  ...
</description>
</item><item>
<title>Market for cellular therapies wil...</title>
<link>http://www.inboxrobot.com/news.php?fid=202003071</link>
<pubDate>5 Dec 2008 13:52 GMT</pubDate>
<description>
...  and/or Europe, Dendreon&#39;s Provenge will be the first market entrant following its approval for prostate cancer in 2009 in the United States. Another cellular therapy that will launch in  ...
</description>
</item><item>
<title>Surgeon&#39;s goals: Smaller incisions</title>
<link>http://www.inboxrobot.com/news.php?fid=201991636</link>
<pubDate>5 Dec 2008 11:56 GMT</pubDate>
<description>
...  are also good for tight areas where there is little room to work, like prostate removal. But robotics - at this point in time - aren&#39;t feasible for most  ...
</description>
</item><item>
<title>Rationing food intake every few weeks could slash men&#39;s risk of prostate cancer.</title>
<link>http://www.inboxrobot.com/news.php?fid=201991387</link>
<pubDate>5 Dec 2008 11:56 GMT</pubDate>
<description>
... Wartime diet of regular fasting slashes prostate cancer risk Last updated at 1:54 PM on 04th December 2008 Rationing food intake  ...
</description>
</item><item>
<title>Light duties for Japan&#39;s emperor</title>
<link>http://www.inboxrobot.com/news.php?fid=201991342</link>
<pubDate>5 Dec 2008 11:56 GMT</pubDate>
<description>
...  his duties were cancelled because his blood pressure shot up. Emperor Akihito, who had prostate cancer surgery in 2003 and now has an irregular pulse, is to undergo further  ...
</description>
</item><item>
<title>DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast</title>
<link>http://www.inboxrobot.com/news.php?fid=201990411</link>
<pubDate>5 Dec 2008 11:54 GMT</pubDate>
<description>
...  strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure&#39;s proprietary molecular marker. This test is also available through  ...
</description>
</item><item>
<title>Geron&#39;s partner Merck initiates Phase I study of cancer vaccine</title>
<link>http://www.inboxrobot.com/news.php?fid=201990223</link>
<pubDate>5 Dec 2008 11:54 GMT</pubDate>
<description>
...  the vaccine candidate in patients with solid tumors, including non-small cell lung cancer and prostate carcinoma. Merck is developing the vaccine candidate under a July 2005 research, development and  ...
</description>
</item><item>
<title>Cell Genesys and Takeda terminate collaboration agreement</title>
<link>http://www.inboxrobot.com/news.php?fid=201990222</link>
<pubDate>5 Dec 2008 11:54 GMT</pubDate>
<description>
...  terms of the agreement, Takeda will return all commercial rights to Gvax immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection  ...
</description>
</item><item>
<title>OncoGenex reports positive survival results from Phase II cancer trial</title>
<link>http://www.inboxrobot.com/news.php?fid=201990219</link>
<pubDate>5 Dec 2008 11:54 GMT</pubDate>
<description>
...  2.4 months over mitoxantrone. The study randomized 82 patients with metastatic or locally recurring prostate cancer refractory to hormone therapy. The median survival was 27.5 months for the patients  ...
</description>
</item><item>
<title>Epitherapeutics Receives Funding from Novo and SEED Capital Denmark for Cancer Drug Development in the</title>
<link>http://www.inboxrobot.com/news.php?fid=201989042</link>
<pubDate>5 Dec 2008 11:52 GMT</pubDate>
<description>
...  an enzyme involved in the regulation of androgen responsive genes for the treatment of prostate cancer. Subsequent developments may identify other potential clinical indications. At present stage nobody really  ...
</description>
</item><item>
<title>Doctors didn&#39;t steal kidney, says hospital</title>
<link>http://www.inboxrobot.com/news.php?fid=201989005</link>
<pubDate>5 Dec 2008 11:52 GMT</pubDate>
<description>
...  expertise in removing kidneys, according to Thach. Urinary Department Head Tran Ngoc Sinh from Cho  ...  tumor, while she was not suffering from kidney stones. However, when she had a check-up at  ...
</description>
</item></channel>
</rss>
